BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29675587)

  • 21. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
    Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior.
    Capuano F; Grami O; Pugliese L; Paulli M; Pietrabissa A; Solcia E; Vanoli A
    Endocr Pathol; 2018 Dec; 29(4):369-373. PubMed ID: 30076568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
    Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
    World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Grading of neuroendocrine tumors].
    Saeger W; Schnabel PA; Komminoth P
    Pathologe; 2016 Jul; 37(4):304-13. PubMed ID: 27379621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN).
    La Rosa S; Uccella S; Molinari F; Savio A; Mete O; Vanoli A; Maragliano R; Frattini M; Mazzucchelli L; Sessa F; Bongiovanni M
    Am J Surg Pathol; 2018 Nov; 42(11):1503-1512. PubMed ID: 30001239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rb Loss and
    Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
    Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
    [No Abstract]   [Full Text] [Related]  

  • 29. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.
    Inzani F; Petrone G; Rindi G
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):463-470. PubMed ID: 30098710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenic ATM Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms.
    Nassereddine H; Chicaud M; Rebah K; Théou-Anton N; Sautet A; Dermer J; Couvelard A
    Endocr Pathol; 2021 Dec; 32(4):517-523. PubMed ID: 34019237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical features and prognostic factors of primary gastric neuroendocrine neoplasms].
    Xiong YJ; Liu XY; Cheng CE; Chen C; Sun YB; Tan CH; Liu YT; Feng J; Ma YF; Shi DT; Li R; Tang QY
    Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):297-302. PubMed ID: 32209196
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
    Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
    Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.
    Uccella S; La Rosa S; Metovic J; Marchiori D; Scoazec JY; Volante M; Mete O; Papotti M
    Endocr Pathol; 2021 Mar; 32(1):192-210. PubMed ID: 33433884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).
    Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R;
    Neuroendocrinology; 2019; 108(1):54-62. PubMed ID: 30153658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on clinicopathologic grading system and prognosis of primary hepatic neuroendocrine neoplasms].
    Zhao J; Yang B; Xu C; Zhang WS; Ji Y; Chen LL; Tan YS; Zeng HY; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2012 Feb; 41(2):102-6. PubMed ID: 22455886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification.
    Endo S; Dousei T; Yoshikawa Y; Hatanaka N; Taniyama K; Yamauchi A; Kamiike W; Nishijima J
    Int Surg; 2012; 97(4):335-9. PubMed ID: 23294075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.
    Shen C; Chen H; Chen H; Yin Y; Han L; Chen J; Tang S; Yin X; Zhou Z; Zhang B; Chen Z
    BMC Gastroenterol; 2016 Sep; 16(1):111. PubMed ID: 27613657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.